PTC Therapeutics Duchenne drug may work, data inconclusive: FDA panel

PTC Therapeutics Inc's experimental drug to treat Duchenne muscular dystrophy, a devastating degenerative disease that mostly affects young boys, may work but the company will need to do more work to prove it, an advisory panel to the U.S. Food and Drug Administration concluded on Thursday.The panel's vote reduces the chance the drug will be approved soon since the FDA generally follows the advice of its advisors.In Europe the drug is approved on a conditional basis, meaning approval must be ren